Primary Analysis Results of the Single‐arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B‐cell Lymphoma (l‐mind)
Year: 2019
Type: article
Source: Hematological Oncology
DOI: 10.1002/hon.130_2629
Institutions: Hospices Civils de Lyon, Hôpital Lyon Sud, Universitätsklinikum Würzburg, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Duran i Reynals Hospital, Jagiellonian University, Azienda Ospedaliera S.Maria, Semmelweis University, University Hospital Olomouc, Palacký University Olomouc, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, CHU Dinant Godinne UCL Namur, UCLouvain, University of Liverpool, Clatterbridge Cancer Centre NHS Foundation Trust, Ludwig-Maximilians-Universität München, University of Bologna, MorphoSys (Germany), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2953058729